~~<i id='4156125DAD'><strike id='4156125DAD'><tt id='4156125DAD'><pre id='4156125DAD'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

fashion

author：explore 2025-09-02 08:13:25 - browse：71

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Listen: Biogen's messy board & Laronde's data problem

Wikipedia

entertainment

focus

hotspot

focus

AphlebotomistcollectvialsofbloodatadonationcenterinSanFrancisco.JustinSullivan/GettyImagesOnequestio

WSS

Trial using CRISPR to edit HIV out of cells disappoints

Republican states more likely to report Covid vaccine side effects

Four alarming medical procedures we’re glad history forgot

Community addresses injustice for Long Island mothers

When is a doctor not a doctor? Try when patients address women doctors

Bird flu reported in person exposed to presumably infected cattle

knowledge

fashion

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Connecting traumatic brain injury and domestic violence

Hepatitis C has a cure — but many Americans still lack access to it

Drug companies' payments and gifts affect physicians' prescribing

After affirmative action ruling, medical educators look to 'holistic review'

Gut bacteria may contribute to kidney autoimmunity, study finds

Medical records are filled with copy

Young boy dies in trial for Pfizer Duchenne gene therapy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Covid silver lining: Unprecedented look at human immune system

entertainment

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Pfizer's Covid pill remains 89% effective in final analysis, company says

People with mental disorders often marry others with same

Australia's humpback populations rebound raising hopes of marine scientists

Option Care buys Amedisys in $3.6 billion home care deal

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

focus

hotspot

focus

focus